Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid

Dupixent; Dupilumab; Sanofi; Regeneron; bullous pemphigoid; FDA approval; type 2 inflammation; autoimmune disease; priority review; orphan drug

Merck’s Enflonsia FDA Approval Spurs Sanofi to Accelerate Beyfortus Supply Ahead of 2025-26 RSV Season

RSV; Infant immunization; Merck; Sanofi; Beyfortus; Enflonsia; FDA approval; supply chain; healthcare; AstraZeneca

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment